Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 152-160 , March 2006

The application of epigenetic modifiers on the treatment of prostate and bladder cancer

  • Zhengwang Zhang, M.D., Ph.D.

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    • ,
  • Jose Karam, M.D.

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    • ,
  • Eugene Frenkel, M.D.

      Affiliations

    • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    • ,
  • Arthur Sagalowsky, M.D.

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    • ,
  • Jer-Tsong Hsieh, Ph.D.

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-214-648-3988; fax: +1-214-648-8786

References 

  1. Wolffe AP , Matzke MA . Epigenetics (Regulation through repression) . Science . 1999;286:481–486
  2. Korzus E , Torchia J , Rose DW , et al.   Transcription factor-specific requirements for coactivators and their acetyltransferase functions . Science . 1998;279:703–707
  3. Bannister AJ , Kouzarides T . The CBP co-activator is a histone acetyltransferase . Nature . 1996;384:641–643
  4. Nan X , Ng HH , Johnson CA , et al.   Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex . Nature . 1998;393:386–389
  5. Herman JG , Baylin SB . Gene silencing in cancer in association with promoter hypermethylation . N Engl J Med . 2003;349:2042–2054
  6. Yegnasubramanian S , Kowalski J , Gonzalgo ML , et al.   Hypermethylation of CpG islands in primary and metastatic human prostate cancer . Cancer Res . 2004;64:1975–1986
  7. Kang GH , Lee S , Lee HJ , et al.   Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia . J Pathol . 2004;202:233–240
  8. Fang MZ , Wang Y , Ai N , et al.   Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines . Cancer Res . 2003;63:7563–7570
  9. Konishi N , Nakamura M , Kishi M , et al.   DNA hypermethylation status of multiple genes in prostate adenocarcinomas . Jpn J Cancer Res . 2002;93:767–773
  10. Henrique R , Jeronimo C , Hoque MO , et al.   Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions . DNA Cell Biol . 2005;24:264–269
  11. Mhawech P , Benz A , Cerato C , et al.   Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation . Mod Pathol . 2005;18:340–348
  12. Urano T , Takahashi S , Suzuki T , et al.   14-3-3sigma is down-regulated in human prostate cancer . Biochem Biophys Res Commun . 2004;319:795–800
  13. Konishi N , Nakamura M , Kishi M , et al.   Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas . Am J Pathol . 2002;160:1207–1214
  14. Herman JG , Jen J , Merlo A , et al.   Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B . Cancer Res . 1996;56:722–727
  15. Padar A , Sathyanarayana UG , Suzuki M , et al.   Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation . Clin Cancer Res . 2003;9:4730–4734
  16. Nakagawa T , Kanai Y , Ushijima S , et al.   DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis . J Urol . 2005;173:1767–1771
  17. Hoffmann MJ , Florl AR , Seifert HH , et al.   Multiple mechanisms downregulate CDKN1C in human bladder cancer . Int J Cancer . 2005;114:406–413
  18. Schlott T , Quentin T , Korabiowska M , et al.   Alteration of the MDM2-p73–P14ARF pathway related to tumour progression during urinary bladder carcinogenesis . Int J Mol Med . 2004;14:825–836
  19. Dulaimi E , Uzzo RG , Greenberg RE , et al.   Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel . Clin Cancer Res . 2004;10:1887–1893
  20. Dominguez G , Silva J , Garcia JM , et al.   Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors . Mutat Res . 2003;530:9–17
  21. Chang LL , Yeh WT , Yang SY , et al.   Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer . J Urol . 2003;170:595–600
  22. Valenzuela MT , Galisteo R , Zuluaga A , et al.   Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer . Eur Urol . 2002;42:622–628
  23. Ribeiro-Filho LA , Franks J , Sasaki M , et al.   CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer . Mol Carcinog . 2002;34:187–198
  24. Dominguez G , Carballido J , Silva J , et al.   p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients . Clin Cancer Res . 2002;8:980–985
  25. Chan MW , Chan LW , Tang NL , et al.   Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients . Clin Cancer Res . 2002;8:464–470
  26. Nishiyama H , Gill JH , Pitt E , et al.   Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1 . Oncogene . 2001;20:2956–2964
  27. Jeronimo C , Henrique R , Hoque MO , et al.   A quantitative promoter methylation profile of prostate cancer . Clin Cancer Res . 2004;10:8472–8478
  28. McKie AB , Douglas DA , Olijslagers S , et al.   Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer . Oncogene . 2005;24:2166–2174
  29. Tokumaru Y , Harden SV , Sun DI , et al.   Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma . Clin Cancer Res . 2004;10:5518–5522
  30. Florl AR , Steinhoff C , Muller M , et al.   Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation . Br J Cancer . 2004;91:985–994
  31. Liu L , Yoon JH , Dammann R , et al.   Frequent hypermethylation of the RASSF1A gene in prostate cancer . Oncogene . 2002;21:6835–6840
  32. Chen H , Tu SW , Hsieh JT . Down regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer . J Biol Chem . 2005;280:22437–22444
  33. Dote H , Toyooka S , Tsukuda K , et al.   Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour . Br J Cancer . 2005;92:1117–1125
  34. Chen H , Toyooka S , Gazdar AF , et al.   Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines . J Biol Chem . 2003;278:3121–3130
  35. Yamanaka M , Watanabe M , Yamada Y , et al.   Altered methylation of multiple genes in carcinogenesis of the prostate . Int J Cancer . 2003;106:382–387
  36. Chan MW , Chan LW , Tang NL , et al.   Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients . Int J Cancer . 2003;104:611–616
  37. Lee MG , Kim HY , Byun DS , et al.   Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma . Cancer Res . 2001;61:6688–6692
  38. Chung WB , Hong SH , Kim JA , et al.   Hypermethylation of tumor-related genes in genitourinary cancer cell lines . J Korean Med Sci . 2001;16:756–761
  39. Enokida H , Shiina H , Urakami S , et al.   Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer . Int J Cancer . 2005;116:174–181
  40. Bastian PJ , Ellinger J , Schmidt D , et al.   GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer (Is there a correlation with clinical stage, Gleason grade, PSA value or age?) . Eur J Med Res . 2004;9:523–527
  41. Bernardini S , Miano R , Iori R , et al.   Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer (A useful diagnostic and prognostic marker?) . Clin Chim Acta . 2004;350:181–188
  42. Woodson K , Hayes R , Wideroff L , et al.   Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites . Prostate . 2003;55:199–205
  43. Harden SV , Guo Z , Epstein JI , et al.   Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma . J Urol . 2003;169:1138–1142
  44. Song JZ , Stirzaker C , Harrison J , et al.   Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells . Oncogene . 2002;21:1048–1061
  45. Lin X , Tascilar M , Lee WH , et al.   GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells . Am J Pathol. . 2001;159:1815–1826
  46. Cairns P , Esteller M , Herman JG , et al.   Molecular detection of prostate cancer in urine by GSTP1 hypermethylation . Clin Cancer Res . 2001;7:2727–2730
  47. Mutaguchi K , Yasumoto H , Mita K , et al.   Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer . Cancer Res . 2003;63:7717–7723
  48. Santourlidis S , Warskulat U , Florl AR , et al.   Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma . Mol Carcinog . 2001;32:36–43
  49. Tada Y , Wada M , Taguchi K , et al.   The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers . Cancer Res . 2002;62:4048–4053
  50. Jeronimo C , Henrique R , Hoque MO , et al.   Quantitative RARbeta2 hypermethylation (A promising prostate cancer marker) . Clin Cancer Res . 2004;10:4010–4014
  51. Zhu X , Leav I , Leung YK , et al.   Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis . Am J Pathol . 2004;164:2003–2012
  52. Takahashi S , Inaguma S , Sakakibara M , et al.   DNA methylation in the androgen receptor gene promoter region in rat prostate cancers . Prostate . 2002;52:82–88
  53. Nojima D , Li LC , Dharia A , et al.   CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma . Cancer . 2001;92:2076–2083
  54. Lau KM , LaSpina M , Long J , et al.   Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells (Regulation by methylation and involvement in growth regulation) . Cancer Res . 2000;60:3175–3182
  55. Jarrard DF , Kinoshita H , Shi Y , et al.   Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells . Cancer Res . 1998;58:5310–5314
  56. Jeronimo C , Henrique R , Campos PF , et al.   Endothelin B receptor gene hypermethylation in prostate adenocarcinoma . J Clin Pathol . 2003;56:52–55
  57. Nelson JB , Lee WH , Nguyen SH , et al.   Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer . Cancer Res . 1997;57:35–37
  58. Kito H , Suzuki H , Ichikawa T , et al.   Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer . Prostate . 2001;49:110–115
  59. Tamada H , Kitazawa R , Gohji K , et al.   Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer . J Bone Miner Res . 2001;16:487–496
  60. Lou W , Krill D , Dhir R , et al.   Methylation of the CD44 metastasis suppressor gene in human prostate cancer . Cancer Res . 1999;59:2329–2331
  61. Verkaik NS , Trapman J , Romijn JC , et al.   Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation . Int J Cancer . 1999;80:439–443
  62. Graff JR , Herman JG , Lapidus RG , et al.   E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas . Cancer Res . 1995;55:5195–5199
  63. Cui J , Rohr LR , Swanson G , et al.   Hypermethylation of the caveolin-1 gene promoter in prostate cancer . Prostate . 2001;46:249–256
  64. Maruyama R , Toyooka S , Toyooka KO , et al.   Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features . Clin Cancer Res . 2002;8:514–519
  65. Horikawa Y , Sugano K , Shigyo M , et al.   Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ . J Urol . 2003;169:1541–1545
  66. Henrique R , Jeronimo C , Hoque MO , et al.   MT1G hypermethylation is associated with higher tumor stage in prostate cancer . Cancer Epidemiol Biomarkers Prev . 2005;14:1274–1278
  67. Enokida H , Shiina H , Igawa M , et al.   CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer . Cancer Res . 2004;64:5956–5962
  68. Jeronimo C , Henrique R , Oliveira J , et al.   Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer . J Clin Pathol . 2004;57:872–876
  69. Osman I , Yee H , Taneja SS , et al.   Neutral endopeptidase protein expression and prognosis in localized prostate cancer . Clin Cancer Res . 2004;10:4096–4100
  70. Youssef EM , Chen XQ , Higuchi E , et al.   Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers . Cancer Res . 2004;64:2411–2417
  71. Wu M , Ho SM . PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model . Oncogene . 2004;23:250–259
  72. Yuan BZ , Durkin ME , Popescu NC . Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers . Cancer Genet Cytogenet . 2003;140:113–117
  73. Fukuhara H , Kuramochi M , Fukami T , et al.   Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer . Jpn J Cancer Res . 2002;93:605–609
  74. Bestor TH . The DNA methyltransferases of mammals . Hum Mol Genet . 2000;9:2395–2402
  75. Rhee I , Bachman KE , Park BH , et al.   DNMT1 and DNMT3b cooperate to silence genes in human cancer cells . Nature . 2002;416:552–556
  76. Liang G , Chan MF , Tomigahara Y , et al.   Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements . Mol Cell Biol . 2002;22:480–491
  77. Hermann A , Schmitt S , Jeltsch A . The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity . J Biol Chem . 2003;278:31717–31721
  78. Okano M , Bell DW , Haber DA , et al.   DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development . Cell . 1999;99:247–257
  79. Robertson KD , Uzvolgyi E , Liang G , et al.   The human DNA methyltransferases (DNMTs) 1, 3a and 3b (Coordinate mRNA expression in normal tissues and overexpression in tumors) . Nucleic Acids Res . 1999;27:2291–2298
  80. Sano H , Sager R . Deoxyribonucleic acid methyltransferase from the eukaryote, Chlamydomonas reinhardi . Eur J Biochem . 1980;105:471–480
  81. Lyko F , Ramsahoye BH , Kashevsky H , et al.   Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila . Nat Genet . 1999;23:363–366
  82. Patra SK , Patra A , Dahiya R . Histone deacetylase and DNA methyltransferase in human prostate cancer . Biochem Biophys Res Commun . 2001;287:705–713
  83. Patra SK , Patra A , Zhao H , et al.   DNA methyltransferase and demethylase in human prostate cancer . Mol Carcinog . 2002;33:163–171
  84. Nakagawa T , Kanai Y , Ushijima S , et al.   DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis . J Urol . 2005;173:1767–1771
  85. Eads CA , Danenberg KD , Kawakami K , et al.   CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression . Cancer Res . 1999;59:2302–2306
  86. Kimura F , Seifert HH , Florl AR , et al.   Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma . Int J Cancer . 2003;104:568–578
  87. Luger K , Mader AW , Richmond RK , et al.   Crystal structure of the nucleosome core particle at 2.8 A resolution . Nature . 1997;389:251–260
  88. Kornberg RD . Chromatin structure (A repeating unit of histones and DNA) . Science . 1974;184:868–871
  89. Kornberg RD , Lorch Y . Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome . Cell . 1999;98:285–294
  90. Kornberg RD , Lorch Y . Chromatin-modifying and -remodeling complexes . Curr Opin Genet Dev . 1999;9:148–151
  91. Rosato RR , Almenara JA , Grant S . The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 . Cancer Res . 2003;63:3637–3645
  92. Sasakawa Y , Naoe Y , Inoue T , et al.   Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo . Cancer Lett . 2003;195:161–168
  93. Richon VM , Sandhoff TW , Rifkind RA , et al.   Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation . Proc Natl Acad Sci USA . 2000;97:10014–10019
  94. Canes D , Chiang GJ , Billmeyer BR , et al.   Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo . Int J Cancer . 2005;113:841–848
  95. Kim JS , Lee S , Lee T , et al.   Transcriptional activation of p21(WAF1/CiP1) by apicidin, a novel histone deacetylase inhibitor . Biochem Biophys Res Commun . 2001;281:866–871
  96. Han JW , Ahn SH , Kim YK , et al.   Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin (Involvement of protein kinase C) . J Biol Chem . 2001;276:42084–42090
  97. Pong RC , Lai YJ , Chen H , et al.   Epigenetic regulation of Coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells . Cancer Res . 2003;63:8680–8686
  98. Goffin J , Eisenhauer E . DNA methyltransferase inhibitors-state of the art . Ann Oncol . 2002;13:1699–1716
  99. Lubbert M . DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies (Clinical results and possible mechanisms of action) . Curr Top Microbiol Immunol . 2000;249:135–164
  100. Bouchard J , Momparler RL . Incorporation of 5-Aza-2′-deoxycytidine-5′-triphosphate into DNA . Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol . 1983;24:109–114
  101. Santi DV , Garrett CE , Barr PJ . On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs . Cell . 1983;33:9–10
  102. Juttermann R , Li E , Jaenisch R . Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation . Proc Natl Acad Sci U S A . 1994;91:11797–11801
  103. Lin KT , Momparler RL , Rivard GE . High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine . J Pharm Sci . 1981;70:1228–1232
  104. Cheng JC , Matsen CB , Gonzales FA , et al.   Inhibition of DNA methylation and reactivation of silenced genes by zebularine . J Natl Cancer Inst . 2003;95:399–409
  105. Jones PA , Taylor SM . Cellular differentiation, cytidine analogs and DNA methylation . Cell . 1980;20:85–93
  106. Jackson-Grusby L , Laird PW , Magge SN , et al.   Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase . Proc Natl Acad Sci U S A . 1997;94:4681–4685
  107. Walker C , Nettesheim P . In vitro transformation of primary rat tracheal epithelial cells by 5-azacytidine . Cancer Res . 1986;46:6433–6437
  108. Thibault A , Figg WD , Bergan RC , et al.   A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer . Tumori . 1998;84:87–89
  109. Cheng JC , Weisenberger DJ , Gonzales FA , et al.   Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells . Mol Cell Biol . 2004;24:1270–1278
  110. Lin X , Asgari K , Putzi MJ , et al.   Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide . Cancer Res . 2001;61:8611–8616
  111. Villar-Garea A , Fraga MF , Espada J , et al.   Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells . Cancer Res . 2003;63:4984–4989
  112. Kelly WK , O’Connor OA , Marks PA . Histone deacetylase inhibitors (from target to clinical trials) . Expert Opin Investig Drugs . 2002;11:1695–1713
  113. Gore SD , Carducci MA . Modifying histones to tame cancer (Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors) . Expert Opin Investig Drugs . 2000;9:2923–2934
  114. Newmark HL , Lupton JR , Young CW . Butyrate as a differentiating agent (Pharmacokinetics, analogues and current status) . Cancer Lett . 1994;78:1–5
  115. Richon VM , Emiliani S , Verdin E , et al.   A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases . Proc Natl Acad Sci U S A . 1998;95:3003–3007
  116. Finnin MS , Donigian JR , Cohen A , et al.   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors . Nature . 1999;401:188–193
  117. Furumai R , Matsuyama A , Kobashi N , et al.   FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases . Cancer Res . 2002;62:4916–4921
  118. LoRusso PM , Demchik L , Foster B , et al.   Preclinical antitumor activity of CI-994 . Invest New Drugs . 1996;14:349–356
  119. Butler LM , Agus DB , Scher HI , et al.   Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo . Cancer Res . 2000;60:5165–5170
  120. Graziano MJ , Pilcher GD , Walsh KM , et al.   Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs . Invest New Drugs . 1997;15:295–310
  121. Kelly WK , Richon VM , O’Connor O , et al.   Phase I clinical trial of histone deacetylase inhibitor (Suberoylanilide hydroxamic acid administered intravenously) . Clin Cancer Res . 2003;9:3578–3588
  122. Richon VM , Sandhoff TW , Rifkind RA , et al.   Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation . Proc Natl Acad Sci USA . 2000;97:10014–10019
  123. Canes D , Chiang GJ , Billmeyer BR , et al.   Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo . Int J Cancer . 2005;113:841–848
  124. Butler LM , Webb Y , Agus DB , et al.   Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase . Clin Cancer Res . 2001;7:962–970
  125. Kuefer R , Hofer MD , Altug V , et al.   Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer . Br J Cancer . 2004;90:535–541
  126. Roy S , Packman K , Jeffrey R , et al.   Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells . Cell Death Differ . 2005;12:482–491
  127. Sasakawa Y , Naoe Y , Sogo N , et al.   Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor . Biochem Pharmacol . 2005;69:603–616
  128. Thelen P , Schweyer S , Hemmerlein B , et al.   Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells . Int J Oncol . 2004;24:25–31
  129. Suenaga M , Soda H , Oka M , et al.   Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells . Int J Cancer . 2002;97:621–625
  130. Goh M , Chen F , Paulsen MT , et al.   Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells . Neoplasia . 2001;3:331–338
  131. Sasakawa Y , Naoe Y , Noto T , et al.   Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors . Biochem Pharmacol . 2003;66:897–906
  132. Glaser KB , Staver MJ , Waring JF , et al.   Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors (Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines) . Mol Cancer Ther . 2003;2:151–163
  133. Stirzaker C , Song JZ , Davidson B , et al.   Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells . Cancer Res . 2004;64:3871–3877
  134. Gottlicher M , Minucci S , Zhu P , et al.   Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells . EMBO J . 2001;20:6969–6978
  135. Mei S , Ho AD , Mahlknecht U . Role of histone deacetylase inhibitors in the treatment of cancer (Review) . Int J Oncol . 2004;25:1509–1519
  136. Sandor V , Bakke S , Robey RW , et al.   Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms . Clin Cancer Res . 2002;8:718–728
  137. Keen JC , Yan L , Mack KM , et al.   A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine . Breast Cancer Res Treat . 2003;81:177–186
  138. Belinsky SA , Klinge DM , Stidley CA , et al.   Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer . Cancer Res . 2003;63:7089–7093
  139. Zhu WG , Otterson GA . The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells . Curr Med Chem Anti-Canc Agents . 2003;3:187–199
  140. Cameron EE , Bachman KE , Myohanen S , et al.   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer . Nat Genet . 1999;21:103–107
  141. Dunn GP , Sheehan KC , Old LJ , et al.   IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression . Cancer Res . 2005;65:3447–3453
  142. Zhang Z , Stanfield J , Frenkel EP , et al.   Histone deacetylase inhibitor FK228 enhances therapeutic efficacy of docetaxel in human androgen independent prostate cancer . Proc Am Assoc Cancer Res . 2005;46(Suppl):125; [Abstract LB-245].
  143. Rashid SF , Moore JS , Walker E , et al.   Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A . Oncogene . 2001;20:1860–1872
  144. Chinnaiyan P , Vallabhaneni G , Armstrong E , et al.   Modulation of radiation response by histone deacetylase inhibition . Int J Radiat Oncol Biol Phys . 2005;62:223–229
  145. Camphausen K , Scott T , Sproull M , et al.   Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation . Clin Cancer Res . 2004;10:6066–6071
  146. Qian DZ , Wang X , Kachhap SK , et al.   The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 . Cancer Res . 2004;64:6626–6634
  147. Fang X , Zheng C , Liu Z , et al.   Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2′-deoxycytidine . Oncol Rep . 2004;12:523–526
  148. Hurtubise A , Momparler RL . Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines . Anticancer Drugs . 2004;15:161–167
  149. Pina IC , Gautschi JT , Wang GY , et al.   Psammaplins from the sponge Pseudoceratina purpurea (Inhibition of both histone deacetylase and DNA methyltransferase) . J Org Chem . 2003;68:3866–3873
  150. Leu YW , Rahmatpanah F , Shi H , et al.   Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation . Cancer Res . 2003;63:6110–6115
  151. Varambally S , Dhanasekaran SM , Zhou M , et al.   The polycomb group protein EZH2 is involved in progression of prostate cancer . Nature . 2002;419:624–629
  152. Chihara Y , Sugano K , Kobayashi A , et al.   Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene . Lab Invest . 2005;85:895–907
  153. Iliopoulos D , Guler G , Han SY , et al.   Fragile genes as biomarkers (Epigenetic control of WWOX and FHIT in lung, breast and bladder cancer) . Oncogene . 2005;24:1625–1633

 This work was supported by a United States Army grant (DAMD17-03-2-0033 and W81XWH-04-1-0222) and the National Institutes of Health (CA95730).

PII: S1078-1439(05)00265-6

doi: 10.1016/j.urolonc.2005.11.004

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 152-160 , March 2006

Article Tools